Highlights
- Compelling cost savings in labour and reagents to laboratories
- Our addressable Immunoassay Diagnostic Test Market Estimated $10.3B* Globally by 2012
- Low technical risk, low clinical risk
- Broad menu of common biomarker tests targeting autoimmune disease, infectious disease and allergic conditions
Milestones Recently Achieved
- US, EU, Canadian clearance for SQiDworks platform
- First SQiDworks platform placed in Canada
- Rheumatoid Arthritis Global clearance
- Celiac clearance in Canada
- Celiac Clearance in USA
Upcoming Milestones
- First quantitative IgX PLEX™ Celiac customer Canada
- Platform to UNC for Vasculitis collaboration
- File quantitative IgX PLEX™ Vasculitis panel for US, Canada, EU
- File Ig DxTx Panel for RA + TNF in Canada
- File quantitative Lupus Panel for US, Canada, EU
- SQiDlite Launch in Non IVD NA markets
Management Team »
Claude Ricks
President and CEO
Andrew Morris,
Chief Financial Officer
Peter Lea, Ph.D.
Chief Scientific Officer
Thomas E.T. O'Connor
SVP Sales and Marketing
Kate Smith
VP Technology
Jaymie Sawyer, Ph.D.
VP Research and Development
Eric Schneider
Claude Ricks
Peter Lea, Ph.D.
Saied Nadjafi
David Williams
Paul Mountain
Peter Winkley
SQI's proprietary microarray technology has unlocked the following that have not been possible with microarray multiplexed technologies:
- Separating and resulting the detection events for both antigens and each class of antibody within the same test well.
- High signal-to-noise ratios enabling diagnostic grade precision and accuracy.
- High speed spot printing that covalently binds capture spots to glass substrates generating reproducible arrays of test spots every well, every plate, every patient.
- Multiple levels of quality control built in to evaluate every well for completeness and precision.
- Automated assay processing and algorithms lead to a complete and traceable result every time.
Autoimmune Pipeline
- RA Qual HC/US
- RA Quant HC/EU
- RA Quant. US
- Celiac Qual HC/US
- Celiac Quant HC/EU
- Celiac Quant US
- Vasculitis 3X Quant
- ANA Qual Screen
- Lupus Quant 12X
- IBD Crohn's / UC 8X
- APS 9X Quant
- Auto Hepatitis Quant
- TNF Companion Quant
- SQiDlite IVD
- SQiDlite RUO
|
IgXplex™ Rheumatoid Arthritis Panel
SQI Diagnostics is excited to introduce the latest advancement in Rheumatoid Arthritis antibody testing. IgXplex™ Rheumatoid Arthritis Panel simultaneously measures RF (IgA, IgG, and IgM) and CCP IgG all within one well. The resulting individual RF isotypes along with CCP IgG provide physicians the tools necessary to detect early RA sufferers sooner and predict disease progression faster.
SQiDworks™ Diagnostic Platform
A fully-automated fluidics workstation, scanner and analytical device used to process SQI Diagnostics' proprietary IgXplex™ microarray tests. The robotic platform fully integrates all assay steps for hands-free work-flow and is compatible with standard lab automation systems. The 'load and go' platform is capable of processing up to 74 patient samples per plate and, 3 plates per run, can produce determinations for up to 888 individual test results in about 4 hours, resulting in significant savings for laboratories.
IgX-Plex™ Assays have the unique ability to multiplex the different varieties of antibodies known as classes or isotypes, which includes IgG, IgA, IgM for each antigen. This provides significant time and labor savings advantages over the traditional methods and offers a unique increased utility of results at the antibody class level. SQI Diagnostics has developed, patented and is the sole provider of IgX-Plex™ Assays that are now available in all of our assays.
Confidence Confirmation: Standards, Controls, and Normalization
SQI Diagnostics believes that assuring clinical accuracy is paramount in product design. We have created a proprietary technology to boost the reproducibility and repeatability of our assays from well to well and plate to plate. Each sample well contains 23 unique Plex-Checks™ data points which allows us to provide state of the art confirmation of standards, controls, and normalization without removing billable well space on the assay plate.
Download the Corporate Fact Sheet »
|
